Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multiple-dose trial of SR604 Injection in adults with von Willebrand disease
ChiCTR2600129725Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SR604 in von Willebrand disease (VWD) (4 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Total annualized bleeding rate (ABR) at Week 24 and over the entire treatment period. Started Aug 2026; status: recruiting.
02
Drugs
SR604
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on ChiCTR2600129725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129725.